Asp-02
Asp-02 is an orally active AMPK activator. Asp-02 reduces non-fasting blood glucose levels, improves body weight, and normalizes elevated serum levels of aspartate transaminase (SGOT), alanine transaminase (SGPT), alkaline phosphatase (ALP), urea and creatinine. Asp-02 can be used in the research of type 2 diabetes.
For research use only. We do not sell to patients.
- CAS No.: 86711-45-7
- Formula: C23H20O2
- Molecular Weight:328.41
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All AMPK Isoforms
More
Biological Activity
Description
In Vitro
Asp-02 exhibits favourable drug-like ADME properties, including high intestinal permeability (3724.85 nm/s), 100% predicted oral absorption, and limited CNS penetration, indicating good pharmacokinetic potential[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Albino Wistar (8-12 weeks old, 140-180 g, male and female, alloxan-nicotinamide-induced type 2 diabetes)[1]
-
Dosage:10 mg/kg
-
Administration:p.o.; daily; 25 days
-
Result:Reduced non-fasting blood glucose from 559.0 mg/dL on Day 0 to 99.3 mg/dL on Day 25, corresponding to an 82.23% reduction in female rats.
Increased body weight by 15.20% over the 25-day period in female rats.
Reduced non-fasting blood glucose from 517.5 mg/dL on Day 0 to 75.5 mg/dL on Day 25, corresponding to an 85.41% reduction in male rats.
Increased body weight by 36.61% over the 25-day period in male rats.
Normalized serum biochemical parameters to near-control values: reduced SGOT to 205 IU/L, SGPT to 81 IU/L, ALP to 214 IU/L, urea to ~57 mg/dL, and creatinine to ~0.93 mg/dL in female rats; reduced urea to ~51 mg/dL and creatinine to ~0.95 mg/dL, with comparable improvements in hepatic enzyme levels in male rats.
Chemical Information
-
CAS No. 86711-45-7
-
Molecular Weight 328.41
-
Formula C23H20O2
-
SMILES
O=C(C1=CC=C(C)C=C1)C=CC2=CC=C(C=C2)OCC3=CC=CC=C3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Nephrotoxicity Study
This protocol assesses nephrotoxicity by combining functional kidney injury readouts, urinary/tissue injury biomarkers, and renal histopathology. Serum creatinine and BUN reflect impaired kidney function, while KIM-1, NGAL, clusterin, osteopontin, IL-18, cystatin C, nephrin, Oat5, urinary protein, glucose, and alkaline phosphatase have been used to detect tubular injury in cisplatin-, gentamicin-, and acetaminophen-induced nephrotoxicity models.
-
Mesenchymal stromal/stem cell osteogenic differentiation
Mesenchymal stromal/stem cells can be induced toward an osteoblast-like lineage in vitro by culture in osteogenic medium containing dexamethasone, ascorbic acid or ascorbate-2-phosphate, and β-glycerophosphate; the differentiation process is commonly evaluated by alkaline phosphatase activity, osteogenic marker expression, collagenous matrix formation, and calcium-rich matrix mineralization. The main readouts are alkaline phosphatase activity as an early osteogenic marker and Alizarin Red S staining as a calcium-deposit readout for mineralized extracellular matrix; Alizarin Red S can be inspected microscopically or extracted and measured colorimetrically at 405 nm.
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Asp-02
- 86711-45-7
- Asp02
- Asp 02
- AMPK
- Aminotransferases (Transaminases)
- Phosphatase
- type 2 diabetes
- human AMPK α2β2 heterotrimers
- alloxan-nicotinamide-induced type 2 diabetic model
- ADME properties
- AMP-activated protein kinase
- Wistar rats
- AMPK α2β2γ1
- AMPK allosteric drug and metabolite site
- Claisen-Schmidt condensation
- human AMPK α2β1 heterotrimers
- Inhibitor
- inhibitor
- inhibit